Newman Ferrara LLP Announces Corporate Governance Investigation of Intra-Cellular Therapies, Inc. - ITCI
January 10 2018 - 2:40PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of Intra-Cellular
Therapies, Inc. (“Intra-Cellular Therapies” or the “Company”)
(NASDAQ:ITCI) into potential breaches of fiduciary duty by the
Company’s Board of Directors (the “Board”).
Intra-Cellular Therapies, headquartered in New York, NY, is a
biopharmaceutical company focused on the discovery and clinical
development of drugs concerning neuropsychiatric and neurological
disorders. Newman Ferrara’s investigation focuses on decisions made
by the Board, without shareholder approval, the result of which
significantly diminish shareholder value and do not benefit the
Company. Considering the Company’s lackluster performance since its
2014 initial public offering, it is clear that the Board lacks the
ability to fairly assess and oversee the Company’s direction and
leadership.
Current Intra-Cellular Therapies stockholders seeking more
information on this matter are invited to contact Newman Ferrara
attorneys Jeffrey Norton (jnorton@nfllp.com) or Ryan Jerome
(rjerome@nfllp.com) to discuss this investigation and their
rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180110006140/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024